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Objectives This study sought to evaluate the impact of frailty in older adults undergoing transcath-
eter aortic valve replacement (TAVR) for symptomatic aortic stenosis.
Background Frailty status impacts prognosis in older adults with heart disease; however, the impact
of frailty on prognosis after TAVR is unknown.
Methods Gait speed, grip strength, serum albumin, and activities of daily living status were col-
lected at baseline and used to derive a frailty score among patients who underwent TAVR proce-
dures at a single large-volume institution. The cohort was dichotomized on the basis of median
frailty score into frail and not frail groups. The impact of frailty on procedural outcomes (stroke,
bleeding, vascular complications, acute kidney injury, and mortality at 30 days) and 1-year mortality
was evaluated.
Results Frailty status was assessed in 159 subjects who underwent TAVR (age 86  8 years, Society
of Thoracic Surgery Risk Score 12  4). Baseline frailty score was not associated with conventionally
ascertained clinical variables or Society of Thoracic Surgery score. Although high frailty score was
associated with a longer post-TAVR hospital stay when compared with lower frailty score (9  6
days vs. 6  5 days, respectively, p  0.004), there were no signiﬁcant crude associations between
frailty status and procedural outcomes, suggesting adequacy of the standard selection process for
identifying patients at risk for periprocedural complications after TAVR. Frailty status was indepen-
dently associated with increased 1-year mortality (hazard ratio: 3.5, 95% conﬁdence interval: 1.4 to
8.5, p  0.007) after TAVR.
Conclusions Frailty was not associated with increased periprocedural complications in patients se-
lected as candidates to undergo TAVR but was associated with increased 1-year mortality after
TAVR. Further studies will evaluate the independent value of this frailty composite in older adults
with aortic stenosis. (J Am Coll Cardiol Intv 2012;5:974–81) © 2012 by the American College of
Cardiology Foundation
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975The phenotype of frailty has emerged in the published data
as an important estimate of overall health status that is
associated with morbidity and mortality in the general
population (1), outcomes in older adults with coronary
artery disease (2,3), and recovery after general (4) and
cardiac surgery (5,6). Severe aortic stenosis (AS) in elderly
persons is a condition in which frailty has been emerging as
an important arbiter of clinical decision-making. Until
recently, the only option for the treatment of severe AS was
See page 982
surgical aortic valve replacement (SAVR). Many older
adults with AS do not receive operative intervention, as a
result of the morbidity of SAVR (7). Although transcatheter
aortic valve replacement (TAVR) provides a less invasive
alternative to SAVR for high-risk patients (8,9), decisions
with regard to the appropriateness of either TAVR or
SAVR hinge on a surgical risk assessment, some of which
depends upon an assessment of patient frailty. However,
frailty is often not objectively measured in the clinical
setting; rather, clinicians often rely on clinical judgment and
risk scores such as the Society of Thoracic Surgery Score
(10) and others (11–13) to determine preoperative risk and
to guide treatment decisions.
Frailty, defined as a syndrome of impaired physiologic
reserve and decreased resistance to stressors (14), is captured
by the core domains of wasting and malnutrition, weakness,
slowness, and inactivity (1) and is closely linked to the
development of subsequent disability (15). We employed a
multi-component frailty assessment in older adults before
TAVR, to evaluate the prognostic implications of baseline
frailty on procedural outcomes and survival after TAVR.
Methods
Participants. A prospective cohort design was used, evalu-
ating 159 high-risk patients presenting to the inpatient or
outpatient Valve Center at Columbia University Medical
Center/New York-Presbyterian Hospital for severe AS who
received TAVR as part of the PARTNER (Placement of
AoRTic TraNscathetER Valve Trial, NCT00530894).
Subjects were 60 years of age and older and had severe,
calcific AS (aortic valve area 0.8 cm2 and mean gradient
40 mm Hg or jet velocity 4.0 m/s). All subjects had
ardiac symptoms of advanced aortic valve disease but
nderwent TAVR after a careful selection process assessing
heir overall candidacy for the procedure. The Columbia
niversity Medical Center Institutional Review Board ap-
roved this protocol, and all participants signed informed
onsent.
Study measurements. Baseline demographic, clinical, and
echocardiographic information was collected for all patients.
With these data, the STS risk score for an isolated SAVR twas computed for each subject and reported as predicted
mortality at 30 days. Markers of frailty were chosen to
loosely parallel those operationalized by Fried et al. (1). Gait
speed was assessed according to time in seconds to walk 15
ft (4.57 m). Participants were instructed to “walk at your
comfortable pace” until a few steps past the 15-ft line. The
timer was started with the first footfall after the 0-ft line and
was stopped at the first footfall after the 15-ft line. The
usual assist devices of subjects (e.g., walkers, canes) were
permitted (16). If able, each subject completed 1 15-ft walk.
Gait speed was calculated by dividing 4.57 m by time to
walk this distance in seconds and reported in meters/second,
as has been previously recommended (17). Those subjects
unable to walk 15 ft were considered to have a gait speed of
0 m/s. Dominant hand grip strength was assessed as the
average of 3 trials of maximal isometric grip measured in
kilograms with a Jamar dynamometer (Sammons Preston,
Chicago, Illinois). Instead of self-reported physical activity,
independence in activities in daily
living (ADLs) was assessed by the
Katz ADL survey (18). The need
for assistance with any 1 of the 6
ADLs resulted in the subject be-
ing considered dependent, and
performing all activities indepen-
dently was required to be consid-
ered independent. Serum albumin
was measured on the day before
TAVR and used as a marker of
malnutrition and wasting.
Outcome measures. All-cause
ortality and procedural out-
omes were prospectively assessed.
rocedural outcomes included in-
ospital life-threatening or major
leeding, major vascular compli-
ations, in-hospital major stroke, in-hospital acute kidney
njury, and 30-day mortality. Life-threatening or major bleed-
ng, major vascular complications, and major stroke were
ssessed according to the Valve Academic Research Consor-
ium criteria (19). Acute kidney injury was defined as stage 2 or
kidney injury according to the Valve Academic Research
onsortium recommended modified RIFLE Criteria (20),
efined as an increase in serum creatinine to 200% or increase
0.3 mg/dl compared with baseline or the need for new renal
eplacement therapy. All-cause mortality at 30 days was as-
essed prospectively. One-year mortality was assessed at semi-
nnual follow-up visits or by phone calls by trained research
ersonnel when follow-up visits were not feasible.
Statistical analysis. The primary predictor variable was a
railty score derived with the markers of frailty. Gait speed
nd serum albumin were divided into quartiles. Grip
trength was divided into quartiles stratified by sex. Given
Abbreviations
and Acronyms
ADLs  activities of daily
living
AS  aortic stenosis
BMI  body mass index
CI  confidence interval
HR  hazard ratio
PCI  percutaneous
coronary intervention
SAVR  surgical aortic valve
replacement
STS  Society of Thoracic
Surgery
TAVR  transcatheter aortic
valve replacementhat more than 75% of subjects were independent in all
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9766 Katz ADLs, ADL status was dichotomized into a group
with dependence in any ADL versus those with no ADL
dependence. With these quartiles, a frailty score was opera-
tionalized in the following manner: 1) quartiles of albumin,
gait speed, and grip strength were assigned values of 0 to 3
in descending order; and 2) a score of 0 for ADLs was
assigned for ADL independence and 3 for any ADL
dependence. These components were then summed to
derive a frailty score for each subject (possible range 0 to 12),
with the highest score representing the most frail, and the
lowest score being the least frail (Table 1).
The cohort was dichotomized at the median frailty score,
and baseline characteristics were compared between groups
with the Student t test or Wilcoxon rank sum for continu-
ous variables and the chi-squared or Fisher exact test for
dichotomous variables as appropriate. Multiple logistic re-
gression was used to evaluate the association of frailty score
with procedural outcomes; the association of frailty markers
and frailty score with long-term survival after TAVR was
assessed with Cox proportional hazards modeling. In sen-
sitivity analyses, frailty score was additionally modeled as a
continuous variable and divided in tertiles. Receiver-
operating curves were used to compare the accuracy of
adding the composite frailty score that included all 4
markers of frailty and scores based on fewer markers of
frailty to a model that included the best clinical variables at
predicting 1-year mortality. Areas under the curve were
compared with the method of DeLong and Delong. Re-
classification analysis was performed according to the
method of Pencina (21). Multivariable models adjusted for
age, access route, and STS score, as well as differences in
baseline characteristics between frailty groups. Due to the
overall low number of clinical events, adjustment covariates
were modeled in separate models to avoid over-fitting and
in a fully adjusted model. Because results were similar, only
results of the unadjusted and fully adjusted models are
presented. Finally, to compare frailty with comorbidity, a
comorbidity score was derived that assigned 1 point for
each of the following conditions: diabetes, atrial fibrilla-
tion, prior coronary revascularization, prior stroke, pe-
ripheral vascular disease, chronic lung disease, glomerular
filtration rate 40 ml/min, hemoglobin 10 g/dl, and
Table 1. Components of Frailty Score
Frailty Domain Measure Frailty Score
Slowness 15-ft walk gait speed
(m/s)
Quartiles (0–3)
Weakness Grip strength (kg) Sex-based quartiles (0–3)
Wasting and malnutrition Serum albumin (g/dl) Quartiles (0–3)
Inactivity Katz activities of daily
living
Any dependence  3,
Independent  0ejection fraction 40%. Pearson’s correlation coefficientswere used to estimate the association between frailty
score and comorbidity score and frailty score and STS
score. All analyses were performed with SAS (version 9.2,
SAS, Cary, North Carolina). A p value of 0.05 was
considered to be statistically significant.
Results
Frailty assessment was performed in 159 older adult patients
before TAVR (transfemoral n  89 or transapical n  70).
he mean age was 86 years, and 50% were men. Most
ubjects were admitted from the community (92% were
ommunity-dwelling, 8% were from a skilled care facility).
hirty subjects were unable to walk 15 ft due to shortness of
reath at rest or extreme deconditioning. Those subjects
ere assigned a gait speed of 0 m/s. Gait speed, grip
trength, serum albumin level, and activity of daily living
tatus is listed in Table 2.
Overall, the prevalence of comorbid illnesses was high,
ecause 50% of subjects had 3 or more comorbid conditions
interquartile range 1). Frailty score was not associated with
number of comorbid illnesses (R2  0.003, p  0.5) or
STS score (R2 0.002, p 0.6). Demographic and clinical
haracteristics did not differ between the groups with high
nd low frailty score (Table 3). Specifically, age, sex, body
ize, cardiac function, severity of AS, and number of
omorbid conditions did not differ between the groups with
igh and low frailty scores. There was a higher prevalence of
yperlipidemia and percutaneous coronary intervention
PCI) among subjects in the group with the lower frailty
core. Hemoglobin was lower among subjects with a higher
railty score. However, B-type natriuretic peptide, leucocyte
ount, and renal function did not differ between groups.
here was no difference in frailty score among those subjects
ho underwent TAVR via the transapical compared with
Table 2. Markers of Frailty
Frailty score 5 (4)
Albumin 3.8 (0.6)
Gait speed
Subjects able to walk 15 feet 0.57 (0.35)
All subjects with walk attempted 0.46 (0.41)
Grip strength
Men 22.0 (11.3)
Women 12.8 (5.8)
Number of independent ADLs
0–1 2 (1%)
2–3 12 (8%)
4–5 23 (14%)
6 122 (77%)
Any ADL impairment 37 (23%)
Values are median (interquartile range) or n (%).ADL activities of daily living; IQR interquartile range.
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977the transfemoral approach (mean frail score 5.3  3.0 vs. 5.4 
3.0, respectively, p  0.83).
Procedural and 30-day outcomes. During the transcatheter
alve procedure there was no difference in the amount of
ontrast used among subjects with a frailty score 5
ompared with those with a lower frailty score (99  64 ml
vs. 86  36 ml, respectively, p  0.7). A high frailty score
was associated with a longer post-TAVR hospital stay when
compared with a lower frailty score (9  6 days vs. 6  5
days, respectively, p  0.004). Overall, at 30 days, among
159 subjects there were 8 (5%) deaths, 1 (1%) in-hospital
stroke, 8 (5%) in-hospital major vascular complications, and
57 (36%) in-hospital life-threatening or major bleeding
events, and 6 (4%) subjects developed acute kidney injury
(Fig. 1). There was no crude association between frailty
status and procedural outcomes. After adjustment for age,
access route, STS score, prior PCI, hyperlipidemia, and
hemoglobin, a frailty score of 5 was associated with
in-hospital life-threatening or major bleeding events (odds
ratio: 2.2, 95% confidence interval [CI]: 1.02 to 4.6, p 
0.04). There was a higher frequency of blood transfusions
after TAVR in the group with a frailty score5 (24 (32.9%)
Table 3. Baseline Characteristics
Overall
(n  159
Age (yrs) 86.2 (7.7)
Female 80 (50%
Body mass index (kg/m2) 24.7 (5.6)
Community dwelling 134 (92%
Transapical access 70 (44%
23-mm valve 62 (40%
Diabetes 37 (23%
Hypertension 95 (79%
Hyperlipidemia 95 (60%
Atrial ﬁbrillation or ﬂutter 67 (42%
Previous percutaneous coronary angioplasty 67 (42%
Previous coronary artery bypass 64 (40%
Previous pacemaker 50 (31%
Previous stroke 14 (9%)
Peripheral vascular disease 41 (26%
Pulmonary disease 47 (30%
Mean gradient (mm Hg) 45 (15)
Aortic valve area (cm2) 0.6 (0.2)
Ejection fraction (%) 48 (16)
Glomerular ﬁltration rate (ml/min) 56 (23)
Platelet count  109/l 202 (67)
B-natriuretic peptide pg/ml 1,411 (1,421
Hemoglobin g/dl 11.3 (1.5)
Leukocyte count  109/l 7.5 (2.8)
STS score (%) 11.9 (3.9)
Values are n (%).
STS Society of Thoracic Surgery.versus 15 (18.1%), p  0.03. There was no statistically 3significant interaction between access route and frailty score
category for the life-threatening or major bleeding
endpoint.
Long-term survival. Follow-up time of 348 days or more
as available for 85% of the cohort. In univariate analysis,
uartiles of gait speed and grip strength were not associated
ith survival after TAVR (p  0.3 and p  0.3, respec-
ively). Subjects with ADL limitation experienced increased
ortality compared with those without any ADL limitation
hazard ratio [HR]: 2.13, 95% CI: 0.97 to 4.71, p  0.07);
owever, these results did not meet statistical significance.
uartiles of serum albumin were associated with increased
ortality after TAVR (HR: 1.51, 95% CI: 1.03 to 2.21, per
ncrease in quartile, p  0.03). Frailty score was associated
ith increased mortality after TAVR when modeled con-
inuously (HR: 1.15, 95% CI: 1.02 to 1.30, per 1 U increase
n frailty score, p 0.02), divided in tertiles (HR: 1.71, 95%
I: 1.01 to 2.89, per increase in tertile, p 0.04), and when
ichotomized at the median (Fig. 2). Even after adjustment
or age, access route, STS score, prior PCI, hyperlipidemia,
nd hemoglobin, a frailty score of 5 was associated with a
-fold increase in mortality after TAVR (adjusted HR:
Frail (Score >5)
(n  76)
Not Frail (Score <5)
(n  83) p Value
87.1 (6.6) 85.4 (8.4) 0.15
40 (53%) 40 (48%) 0.58
25.0 (6.4) 24.5 (4.9) 0.58
61 (90%) 73 (94%) 0.39
30 (39%) 40 (48%) 0.27
28 (37%) 34 (41%) 0.69
19 (25%) 18 (22%) 0.65
58 (76%) 67 (81%) 0.50
38 (50%) 57 (69%) 0.02
34 (45%) 83 (40%) 0.53
22 (29%) 45 (54%) 0.001
27 (36%) 37 (45%) 0.25
24 (32%) 26 (31%) 0.97
9 (12%) 5 (6%) 0.20
16 (21%) 25 (30%) 0.19
22 (29%) 25 (30%) 0.39
45 (15) 45 (15) 0.94
0.6 (0.2) 0.6 (0.2) 0.33
47 (15) 49 (17) 0.48
54 (21) 57 (25) 0.45
201 (71) 203 (64) 0.82
1,498 (1,245) 1,333 (1,564) 0.06
11.1 (1.6) 11.6 (1.5) 0.055
7.7 (3.1) 7.3 (2.4) 0.46
11.9 (4.0) 12.1 (3.9) 0.72)
)
)
)
)
)
)
)
)
)
)
)
)
)
).51, 95% CI: 1.43 to 8.62, p  0.006), (Table 4).
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978Comorbidity score was not associated with long-term mor-
tality in this population (p  0.3). Furthermore, in a model
controlling for comorbidity score, frailty score remained
significantly associated with mortality (HR: 1.15, 95% CI:
1.01 to 1.37, for each unit increase in frailty score, p 
0.03). There was no statistically significant interaction
between access route and frailty score category when exam-
ining the association between frailty and long-term mortal-
ity. Adding the frailty score to clinical predictors of 1-year
mortality increased the area under the receiver-operating
curve; however, the change in area under the curve was not
statistically significant. Similarly, the net reclassification
improvement of 0.24 did not meet statistical significance (p 
0.19) (Table 5).
Figure 1. Unadjusted Clinical OutcomesFigure 2. Kaplan-Meier Survival Estimates Stratified by Frailty ScoreDiscussion
We found that in older adults with AS undergoing TAVR:
1) frailty status as estimated by a composite of grip strength,
gait speed, ADL status, and serum albumin was not
associated with clinical factors or risk scores used in
traditional risk assessment in this population; 2) although
after adjustment for important baseline differences frailty
status was associated with bleeding outcomes, it did not
seem to be associated with other adverse periprocedural
events, including vascular complications, acute kidney
injury, stroke, or procedural mortality; and 3) frail status
was independently associated with reduced long-term
survival after TAVR. Before considering the implications
Table 4. Association of Markers of Frailty and Frailty Score With
Long-Term Survival After TAVR
Model HR (95% CI) p Value
Quartile of grip strength 1.18 (0.84–1.66) 0.3
Quartile of gait speed 1.19 (0.82–1.72) 0.3
Any ADL limitation 2.13 (0.97–4.71) 0.07
Quartile of serum albumin 1.51 (1.03–2.21) 0.03
Score 1.15 (1.02–1.30) 0.02
Adjusted score* 1.15 (1.02–1.30) 0.03
Score 5 3.16 (1.33–7.51) 0.009
Adjusted score 5* 3.51 (1.43–8.62) 0.006
*Adjusted for age, access route, Society of Thoracic Surgery score, prior percutaneous coronary
intervention, hyperlipidemia, and hemoglobin.
ADL activities of daily living; CI confidence interval; HR hazard ratio; TAVR transcath-eter aortic valve replacement.
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979of these findings, however, some methodological issues
are addressed.
First, all patients included in this study were carefully
evaluated and deemed to be appropriate candidates for
TAVR and met the strict inclusion criteria for the
PARTNER Trial. Furthermore, these subjects represent
the earliest U.S. TAVR experience characterized by ad-
vanced age, a high burden of comorbid illness, and a high
prevalence of frailty. Therefore, the generalizability of these
findings to unselected or lower-risk populations or to a
population undergoing traditional SAVR is unknown. For
these reasons, it is important to continue to evaluate these
markers of frailty and others in larger cohorts of older adults
undergoing TAVR and SAVR.
Further methodological concerns relate to the compo-
nents of the frailty score. Although we believe the compo-
nents are reasonable, they do represent a departure from
previously validated frailty assessment tools (1). Specifically,
low albumin and disability might be the result of frailty
and/or chronic disease and not frailty per se. However, the
prognostic value of a score that contains ADL status and
serum albumin suggests that assessing the domains of
malnutrition and disability does predict outcomes in this
high-risk population. Furthermore, our measure of disabil-
ity was an assessment of ADL. Because ADL dependence
develops late and is present among the most vulnerable
subset of subjects, this finding might not prove to be
generalizable to lower-risk cohorts. An assessment of in-
strumental ADL captures earlier manifestation of depen-
dence and disability and might prove to be complementary;
however, these data were unavailable. Despite evidence for
sarcopenic obesity and a high prevalence of frailty in obese
older adults (22), clinicians often associate low body mass
index (BMI) with the frailty phenotype. Therefore we
included BMI in an exploratory frailty model. However, the
model that included BMI was not superior to the frailty
index alone.
An additional statistical concern relates to the value of the
composite compared with single-item measures. The area
Table 5. Receiver-Operating Curve for 1-Year Mortality
Model Area 95% CI
Clinical model* 0.727 0.62–0.83
Clinical model  score that includes albumin 0.734 0.63–0.83
Clinical model  score that includes albumin
and ADL status
0.749 0.64–0.85
Clinical model  score that includes albumin,
ADL status, and gait speed
0.767 0.68–0.85
Clinical model  score that includes albumin,
ADL status, gait speed, and grip strength
0.772 0.68–0.86
*Clinical model includes access route, sex, history of stroke, and hyperlipidemia.
ADL activities of daily living; CI confidence interval.under the receiver-operating curve was highest when the frailtyscore that included albumin, ADLs, gait speed, and grip
strength was added to selected clinical variables. This suggests
that in this population a multi-item composite outperforms
single-item assessment tools. However, due to the small
sample size and the limited number of clinical events, the CIs
for the areas under the curve were wide, and these results did
not meet statistical significance. Therefore, larger studies will
be needed to definitively determine the superiority of this
composite compared with more limited models.
Finally, although this study is an important first step in
establishing the prognostic importance of frailty in older
adults with AS who receive TAVR, many questions remain
unanswered. What is the impact of comorbidity on the
development of frailty in older adults with AS? In this
cohort, frail subjects received fewer PCIs. However, this
dataset cannot establish that incomplete revascularization
and residual ischemia contribute to the vulnerability associ-
ated with the frailty phenotype. Despite the only partial
overlap of frailty and comorbidity in epidemiological studies
(23), further studies should be designed to explore the
association of cardiac and noncardiac comorbid illnesses
with the development of frailty in older adults with AS.
Furthermore, the impact of social support, access to health
care, and socioeconomic status on frailty or on outcomes in
frail older adults with cardiac disease remains unexplored.
Cognitive impairment is closely linked to cardiovascular
disease, adverse cognitive and clinical outcomes after cardiac
surgery, early mortality, and permanent institutionalization
in older adults (24–27). The impact of cognitive impair-
ment on clinical outcomes after TAVR is an important area
that requires further study, because older adults might
benefit from a formal cognitive evaluation to optimize
patient selection and complement formal cardiovascular risk
assessment. The association with frailty and cognitive status
in this population remains unknown.
Additionally, a better understanding of the clinical out-
comes related to frailty is needed. We did not identify
associations with frailty status and vascular complications,
stroke, acute kidney injury, or procedural mortality, albeit
we lacked statistical power due to the low overall rate of
these events. Alternatively, this might suggest that the
rigorous screening process successfully selected for patients
at low risk for peri-procedural events. The association
between frailty markers and increased bleeding has been
previously identified (28); however, the mechanism under-
lying the higher bleeding rate in the frail group requires
further investigation. The higher transfusion rate seen in the
frail group might be related to more bleeding events seen or
a lower baseline hemoglobin. The impact of the higher
bleeding rate on outcome in frail older adults will require
larger multicenter evaluation. Further studies will be needed
to address the impact of frailty on additional important
endpoints, including quality of life, repeat hospital stay
rates, and causes of death.
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980Despite these methodological limitations, our findings
suggest that assessment of these 4 frailty markers could
enhance the preoperative evaluation of high-risk older
adults with severe AS. This study is not the first to study the
impact of frailty in older adults with cardiac disease. With a
standardized global clinical measure of fitness and frailty
according to the methodology of Rockwood (29), Ekerstad
et al. (3) identified approximately one-half of older adults
hospitalized with a non-ST-segment elevation myocardial
infarction as frail. In that cohort frailty was associated with
a 5-fold increase in 1-month mortality (3). Sundermann et
al. (6) employed a frailty assessment that incorporates
Fried’s criteria (1) with an additional 5-item physical
performance evaluation, 3-item laboratory evaluation, and
respiratory function testing in a population of patients
undergoing high-risk cardiac surgery. They found that the
severely frail had a markedly increased surgical mortality,
compared with moderately frail and not frail (22% vs. 8%
and 4%, respectively) (6). In a cohort of TAVR subjects,
Ewe et al. (30) demonstrated that baseline left ventricular
ejection fraction and frailty (with Fried criteria [1]) were
independent predictors of short-term survival after TAVR,
a finding consistent with ours.
Other investigators have moved toward using gait speed
as a single-item performance measure to identify the frailty
phenotype, because gait speeding is a robust independent
predictor of morbidity and mortality in the general popula-
tion and in adults with cardiovascular disease (17,31,32).
Purser (2) performed frailty assessment in older adults
hospitalized for severe coronary artery disease with 2 sepa-
rate composite indexes based on the work of Fried (1) and
Rockwood (29). With Fried’s index, the overall prevalence
of frailty in older adults with CAD was 27% (2). They
found that the utility of single-item measures for identifying
frailty was greatest for gait speed and that impaired gait
speed predicted mortality at 6 months (2). Afilalo et al. (5)
evaluated gait speed as a predictor of outcomes in elderly
patients undergoing cardiac surgery and found that 46% of
adults evaluated were frail (gait speed 0.76 m/s) and that
frailty was associated with a 2- to 3-fold increase in risk of
operative morbidity (stroke, acute renal failure, reoperation,
prolonged ventilation, sternal wound infection) and mortality.
On the basis of these results, gait speed determined by 5-m
walking time is being incorporated into STS and American
College of Cardiology registries and risk prediction tools (33).
In contrast, gait speed as a single item was not associated
with survival after TAVR in the cohort we studied. This
might be due to the high prevalence of extremely slow gait
speed in this population. Indeed, with their cut points (0.7
to 0.76 m/s) 80% of the TAVR population would be
classified as frail. However, there are significant differences
between the cohorts. Among the cardiac surgery subjects
mean age was 76 years, all were considered surgical candi-
dates with a mean STS score of 3% for mortality, and therewas a low prevalence of ADL disability (5). Among the
cohort of hospitalized patients with coronary disease, mean
age was 77 years, and mean gait speed was 0.71  0.29 m/s,
representing a cohort that is younger and more functional.
In contrast, our study subjects were older (mean age 86
years) and had a median gait speed of 0.57 m/s and a mean
STS score for mortality of 12%. Epidemiological data
suggest that slow gait speed is the first manifestation of the
frailty phenotype to develop, whereas shrinking occurs at a
more advanced stage (34). An ADL dependence, often a
consequence of frailty and comorbidity, is also a later
phenomenon (23). In lower-risk populations with a wider
range of gait speed, gait speed seems to capture the frailty
phenotype and is a useful prognostic tool. This study
demonstrates that in a sample of older and frailer
patients, gait speed did not have independent risk pre-
diction; instead, a composite index that includes ADL
status and an index of malnutrition was better than gait
speed for identifying frailty-related risk after TAVR.
This highlights one potential advantage to using a
composite index that includes early and late manifesta-
tions of frailty, namely the ability to discriminate risk
across the spectrum of frailty.
Conclusions
A frailty score based on grip strength, gait speed, ADL,
and serum albumin provides independent prognostic
information in a cohort of older adults undergoing
TAVR for severe symptomatic AS. Further studies must
continue to evaluate the impact of frailty in older adults
with severe AS and other cardiovascular disease and
explore how to facilitate routine frailty assessment before
major cardiac interventions.
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